Seneffe, Belgium, July 06, 2018. Eckert & Ziegler BEBIG entered the South African seed implant market with its IsoSeed® I25.S06. The first patients were successfully treated in Polokwane, Limpopo.
IsoSeed® - Loose seeds for implantation with the Mick® TP/TPV Applicator
The Eckert & Ziegler BEBIG company, Mick Radio-Nuclear Instruments, Inc., is already well known in the South African LDR prostate brachytherapy community for its Mick® TP/TPV Applicator. Now, Eckert & Ziegler BEBIG has entered the market for seeds with IsoSeed® I25.S06 loaded in Mick® Magazines. "We are happy that we are now able to offer our patients a growing spectrum of cancer treatment options", says Dr. Tumelo Brian Moyaba, Chief Oncologist in Polokwane who is supported by the urologists Dr. Lekhotla Richard Monare and Dr. Puleng Magnus Masegela as well as the physicist Stanley Makgere.
Dr. Harald Hasselmann, Managing Director of Eckert & Ziegler BEBIG and Member of the Board of Directors of Eckert & Ziegler AG, adds: "Eckert & Ziegler BEBIG is looking forward to enlarging its LDR brachytherapy business in South Africa. With over 40 years of experience in this field, and an established base of HDR brachytherapy equipment installed in the country, we have already proven to be an innovative and reliable partner."
About LDR brachytherapy
In this form of treatment, small radioactive iodine-125 sources, so called seeds, are placed inside the prostate. By placing the seeds evenly throughout the organ, the prostate is covered with the designated dose required to destroy the cancerous cells. Since irradiation is mainly localized around the radioactive source, neighboring tissues are spared unnecessary damage.
LDR or permanent brachytherapy is the most conservative treatment method for early-stage prostate cancer. Its international popularity has increased continuously since the early 1990s and it is now generally accepted as a state-of-the art therapy. Prostate seed implantation is an effective and well-tolerated method for curing prostate cancer. The cure rates are comparable to the ones of external beam radiation therapy and prostatectomy for early-stage prostate cancer.
About Eckert & Ziegler BEBIG
My partner in brachytherapy and radiation therapy
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the healthcare industry. Its core business is the production and distribution of medical products for the treatment of cancer, using brachytherapy. The company's headquarters are in Belgium, with production facilities in Germany and the USA, as well as subsidiaries throughout Europe, the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company's products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists.
Eckert & Ziegler BEBIG employs approximately 145 people. The company has been listed on the Euronext stock exchange since April 1997.
Contact:
Annica Witt
Marketing Communication Manager
marketing@bebig.com
www.bebig.com